Category: PRESS RELEASES

05
November 2024
Enterome to Present Immunotherapy Pipeline Updates at Upcoming Investor Meetings
Read more
11
June 2024
Enterome to Present Data on OncoMimics™ Approach to Cancer Immunotherapy at EACR 2024
Read more
24
May 2024
Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
Read more
25
April 2024
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more
17
April 2024
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
Read more
06
March 2024
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
Read more
18
December 2023
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
Read more
20
November 2023
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
Read more
13
November 2023
Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023
Read more

Enterome

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Email: info@enterome.com
Metro Station: Ledru-Rollin (Line 8)